HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms. HeartBeam, Inc. was incorporated in 2015 and is based in Santa Clara, California.…
HeartBeam, Inc. Q3 2026 Earnings Call Summary
HeartBeam (NASDAQ: BEAT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 16 employees.
The shares were at 0.2751 USD on 20 November 2026, down 83.3% over 52 weeks. Its 52-week range is 0.2727 USD to 4.000 USD, and it trades at the bottom of that range.
Its market capitalisation is 17.42M USD.
HeartBeam reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 8.72M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 March 2027.